SCHEMBL4782995

SCHEMBL4782995

CC(C)C1(O)CCN(Cc2ccccc2)C1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 3/20 0.54
POLB P06746 1/20 0.53
CYP2D6 P10635 5/20 0.49
ALDH1A1 P00352 1/20 0.49
KDM4E B2RXH2 1/20 0.49
KMT2A Q03164 1/20 0.49
CCR3 P51677 1/20 0.49
OPRM1 P35372 1/20 0.49
OPRD1 P41143 1/20 0.49
OPRK1 P41145 1/20 0.49
CYP3A4 P08684 3/20 0.49
HSD17B10 Q99714 1/20 0.49
TSHR P16473 2/20 0.48
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485326 0.90 OPRL1 (0.61) OPRL1POLBCYP2D6ALDH1A1KDM4E
SCHEMBL14349296 0.79 CYP3A4 (0.50) OPRL1POLBCYP2D6ALDH1A1KMT2A
SCHEMBL11370652 0.79 CYP2D6 (0.60) OPRL1POLBCYP2D6ALDH1A1KMT2A
SCHEMBL13864819 0.79 OPRL1 (0.55) OPRL1POLBCYP2D6ALDH1A1KDM4E
SCHEMBL951796 0.79 OPRL1 (0.58) OPRL1POLBCYP2D6KDM4EKMT2A
SCHEMBL19613477 0.79 OPRL1 (0.58) OPRL1POLBCYP2D6KDM4EKMT2A
SCHEMBL8199005 0.78 OPRL1 (0.62) OPRL1POLBCYP2D6ALDH1A1KDM4E
SCHEMBL15447121 0.78 SIGMAR1 (0.61) OPRL1POLBCYP2D6ALDH1A1KDM4E
SCHEMBL27010358 0.78 CYP3A4 (0.49) OPRL1POLBCYP2D6ALDH1A1KMT2A
SCHEMBL23744794 0.78 OPRL1 (0.61) OPRL1POLBCYP2D6ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025264645-A1 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2025-12-26 WO disclosed
WO-2008041090-A1 MALANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONIST PYRIDINONES PFIZER LIMITED (GB) 2008-04-10 WO disclosed
WO-2008041090-A1 MALANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONIST PYRIDINONES PFIZER LIMITED (GB) 2008-04-10 WO disclosed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US disclosed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US disclosed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones MCHR1, MCHR2, MC1R OPRL1 91/4885POLB 4534/4885CYP2D6 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.